<DOC>
	<DOCNO>NCT02848911</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) patient acute lymphoblastic leukemia ( ALL ) determine safety tolerability increase dos different infusion time AFM11 infusion patient adult B-precursor ALL</brief_summary>
	<brief_title>Safety Study Assess AFM11 Patients With Relapsed Refractory Adult B-precursor ALL</brief_title>
	<detailed_description>Acute lymphoblastic leukemia ( ALL ) aggressive type leukemia characterize overproduction lymphoblasts lymphocytes bone marrow peripheral blood ; frequently accompany suppression normal hematopoiesis . It spread lymph node , spleen , liver , central nervous system ( CNS ) , organ ( sanctuary site ) . Without treatment , ALL usually progress quickly . B- T-cell lymphoblastic leukemia cell express surface antigen parallel respective developmental lineage . Precursor B-cell ALL cell typically express CD10 , CD19 , CD34 surface , along nuclear terminal deoxynucleotide transferase . About 20 % adult ALL patient cytogenetic abnormality indistinguishable Philadelphia chromosome ( Ph1 , ( 9 ; 22 ) ) , accord National Cancer Institute ( NCI ) . The rationale use AFM11 base ability bind malignant cell via anti-CD19 domain T-cells via anti-CD3 domain . This result formation `` immunological synapse '' subsequent T-cell activation lead kill malignant cell . AFM11 2 bind site CD19 2 CD3 , molecular weight ~ 105kDa compare diabodies like blinatumomab one binding site target much low molecular weight ~ 55kDa . In addition , preclinical experiment show AFM11 100 fold high affinity CD3 compare diabodies induce high cytotoxicity vitro presence low effector : target cell ratio . These difference might allow shorten infusion time potentially high clinical efficacy compare blinatumomab .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<criteria>1 . Patients CD19+ Bprecursor Philadelphiachromosome negative ALL relapse least induction consolidation refractory disease candidate bone marrow transplant ( include peripheral blood hematopoietic stem cell transplant [ HSCTs ] ) curative intent time screen 2 . Patients CD19+ Philadelphiachromosome positive ALL fail intolerant therapy least 2 approved tyrosine kinase inhibitor 3 . More 5 % blast bone marrow 4 . In patient high tumor burden ( e.g. , 50 % blast , 15,000 blast /µL blood , elevate lactate dehydrogenase [ LDH ] ) &gt; 2 × upper limit normal [ ULN ] ) , pre treatment 10 mg/m2 dexamethasone 200 mg cyclophosphamide could administer 5 day . 5 . Patients gender , age ≥ 18 6 . Homogenous CD19 expression leukemic blast must confirm either : 1 . Prior result CD19+ stain flow cytometry recent available diagnostic bone marrow biopsy aspirate , 2 . Submission recent bone marrow biopsy stain CD19 positivity . The result test need available prior start AFM11 treatment . 7 . Eastern Cooperative Oncology Group performance status ≤ 2 8 . Life expectancy least 3 month 9 . Ability understand patient information inform consent form 10 . Signed date write informed consent 1 . Autologous HSCT within 3 month prior start AFM11 treatment 2 . Active acute chronic graftversushost disease . All graftversushost disease medication omit least 4 week prior start AFM11 treatment . 3 . Allogeneic HSCT within 3 month prior start AFM11 treatment 4 . Prior treatment blinatumomab CD19 target Tcell engager , include CD19 CART cell 5 . Treatment donorlymphocyte infusion within 4 week start AFM11 treatment exist Graft versus Host Disease ( GvHD ) 6 . Known suspected central nervous system ( CNS ) involvement : 1 . Evidence presence malignant disease , inflammatory lesion , and/or vasculitis cerebral magnetic resonance imaging ( MRI ) 2 . Infiltration cerebrospinal fluid malignant Bcells , confirm lumbar puncture 7 . History current relevant CNS pathology epilepsy , seizure , paresis , aphasia , apoplexia , severe brain injury , cerebellar disease , organic brain syndrome , psychosis 8 . Cancer chemotherapy within 4 week prior start AFM11 treatment , least 4 time respective halflives , whichever longer 9 . Therapy antibody , antibody construct within 4 week prior start AFM11 treatment , least 4 halflives , whichever longer 10 . Treatment investigational agent within 4 week prior start AFM11 treatment , least 4 time respective halflife , whichever longer 11 . Contraindication concomitant medication 12 . Abnormal renal hepatic function follow : aspartate aminotransferase ( AST SGOT ) and/or alanine aminotransferase ( ALT SGPT ) ≥ 2.5 × ULN ; total bilirubin ≥ 1.5 × ULN ; serum creatinine ≥ 2 × ULN ; creatinine clearance &lt; 50 mL/minute 13 . History malignancy Bcell lymphoma Bprecursor ALL within 5 year prior study entry , exception basal cell carcinoma skin carcinoma situ cervix 14 . Uncontrolled infection ; know bacteremia 15 . Any concurrent disease medical condition deem interfere conduct study judge Investigator 16 . Clinically relevant coronary artery disease ( New York Heart Association [ NYHA ] functional angina classification III/IV ) , congestive heart failure ( NYHA III/IV ) , high risk know uncontrolled arrhythmia 17 . Regular dose corticosteroid 4 week prior start AFM11 treatment study anticipate need corticosteroid exceed prednisone 20 mg/day equivalent , immunosuppressive therapy within 4 week prior study entry . Exception pre treatment rapidly progress disease 18 . Known infection human immunodeficiency virus chronic acute infection hepatitis B hepatitis C virus 19 . Pregnant nursing woman woman childbearing potential willing use effective form contraception participation study least 3 month thereafter . Male patient willing ensure study least 3 month thereafter father take place . Effective method contraception include intrauterine device ( IUD ) , combine ( estrogen progesteronecontaining ) hormonal contraception ( oral , vaginal ring transdermal patch ) ethinylestradiol dose least 30 µg , plus use male condom ( preferably spermicide ) , female condom , female diaphragm , cervical cap .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
</DOC>